drugset / Trial / NCT03137004
Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
A single-arm phase II study to evaluate the efficacy and safety of docetaxel plus S-1 (DS) as second-line treatment in patients with AGC.
Timeline
- Start
- 2017-06-01
- Primary completion
- 2018-04-10
- Completion
- 2018-10-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 50 mg/m2 | — |
| Subject | S-1 | Small molecule | 40 mg/m2 | Oral |
| Subject | S-1 | Small molecule | 80 mg | Oral |
| Subject | S-1 | Small molecule | 100 mg | Oral |
| Subject | S-1 | Small molecule | 120 mg | Oral |